What patent is “Plegridy” covered by in the US?
Plegridy (peginterferon beta-1a) is protected in the U.S. by one or more patents covering aspects of the drug, such as its composition, formulations, and/or manufacturing. To say exactly which U.S. patents apply (and their expiration dates), the specific patent numbers or the “Orange Book” listing for Plegridy are needed.
When would Plegridy’s US patent protection expire?
The expiration depends on:
- the specific U.S. patent(s) listed for Plegridy,
- whether any exclusivity (for example, regulatory exclusivity) extends protection beyond patent expiry, and
- any patent litigation, stays, or other legal events that delay generic/biosimilar entry.
Without the exact patent numbers or a cited listing source, no reliable expiration date can be provided.
Are there any recent legal disputes or challenges that affect US availability?
Generic drugs and biosimilars can face delayed market entry if a challenger contests a patent listed for the reference product or if courts impose a stay. Whether that applies to Plegridy depends on current litigation status, which must be checked against the latest public filings and patent-status databases.
Can biosimilars or generics launch in the US before the last patent expires?
Usually not. In the U.S., additional market-entry triggers and “patent listing” rules can prevent approval/launch until the relevant listed patents expire or are found not infringed/invalid (or if other legal milestones are reached).
If you tell me whether you mean:
1) “When does the last Plegridy patent expire in the US?” or
2) “Which specific Plegridy patents are in the US, and what are their expiry dates?”
…I can format the answer around the exact patent listing you care about—if you share the patent numbers or a link to the Orange Book entry you’re looking at.